Low-grade serous ovarian cancer: expert consensus report on the state of the science.
Grisham RN, Slomovitz BM, Andrews N, Banerjee S, Brown J, Carey MS, Chui H, Coleman RL, Fader AN, Gaillard S, Gourley C, Sood AK, Monk BJ, Moore KN, Ray-Coquard I, Shih IM, Westin SN, Wong KK, Gershenson DM.
Int J Gynecol Cancer. 2023 Sep 4;33(9):1331-1344. doi: 10.1136/ijgc-2023-004610.
PMID:37591609
Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma.
Böhm S, Faruqi A, Said I, Lockley M, Brockbank E, Jeyarajah A, Fitzpatrick A, Ennis D, Dowe T, Santos JL, Cook LS, Tinker AV, Le ND, Gilks CB, Singh N.
J Clin Oncol. 2015 Aug 1;33(22):2457-63. doi: 10.1200/JCO.2014.60.5212. Epub 2015 Jun 29.
PMID:26124480
Low grade serous ovarian cancer - A rare disease with increasing therapeutic options.
Zwimpfer TA, Tal O, Geissler F, Coelho R, Rimmer N, Jacob F, Heinzelmann-Schwarz V.
Cancer Treat Rev. 2023 Jan;112:102497. doi: 10.1016/j.ctrv.2022.102497. Epub 2022 Dec 10.
PMID:36525716
Low-grade serous ovarian carcinoma: an evolution toward targeted therapy.
Voutsadakis IA.
Int J Gynecol Cancer. 2020 Oct;30(10):1619-1626. doi: 10.1136/ijgc-2019-000832. Epub 2019 Nov 27.
PMID:31780569
The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma.